Regeneron Pharmaceuticals

Health Care Biotechnology Tarrytown, New York Last filing Feb 4, 2026 · FY2025

                    Revenue
                    FY2025
                
$14.3B
                    3y CAGR +5.6%
                    
                    P56
                    
                    +1.0%
                    
                    Net income
                    FY2025
                
$4.5B
                    Net margin +31.4%
                    
                    P97
                    
                    +2.1%
                    
                    Total assets
                    FY2025
                
$40.6B
                    ROA +11.1%
                    
                    P75
                    
                    +7.4%
                    
                    Operating cash flow
                    FY2025
                
$5.0B
                    
                    +12.6%

18 yrs · FY2008–FY2025 9 filed · 0 derived · 0 blank

1Y 3Y 5Y 10Y

Dollars % of revenue % of assets YoY % CAGR

Each cell as a share of that year’s total assets.

Balance Sheet

Assets, liabilities, and equity

30 accounts · 5 years

Total assets $40.6B

Total liabilities $9.3B

Shareholders equity $31.3B

Account	2025	2024	2023	2022	2021
Assets
Cash and Cash Equivalents	7.7%	6.6%	8.3%	10.6%	11.3%
Accounts Receivable	14.2%	16.5%	17.1%	18.2%	23.7%
Inventory	7.9%	8.2%	7.8%	8.2%	7.7%
Prepaid Expenses	1.2%	0.9%	1.2%	1.4%	1.3%
Other Current Assets	4.5%	3.0%	1.3%	1.2%	0.9%
Total Current Assets	44.4%	49.4%	58.9%	54.4%	55.1%
Property,Plant and Equipment	12.6%	12.2%	12.5%	12.9%	13.7%
Intangible Assets	3.1%	3.0%	3.1%	3.1%	0.0%
Deferred Tax Assets	10.1%	8.8%	7.8%	5.9%	3.4%
Other Noncurrent Assets	4.5%	3.0%	1.3%	1.2%	0.9%
Total Assets	100.0%	100.0%	100.0%	100.0%	100.0%
Liabilities
Accounts Payable	2.3%	2.1%	1.8%	2.0%	2.2%
Accrued Liabilities	7.1%	1.5%	2.0%	2.2%	1.5%
Deferred Revenue	1.4%	1.7%	1.4%	1.6%	1.7%
Current Portion of Long Term Debt	4.9%	5.3%	6.0%	6.8%	7.8%
Other Current Liabilities	0.0%	0.6%	0.0%	0.0%	1.3%
Total Current Liabilities	10.8%	10.4%	10.3%	10.8%	15.5%
Long Term Debt	4.9%	5.3%	6.0%	6.8%	7.8%
Deferred Revenue Noncurrent	0.5%	0.5%	0.4%	0.2%	0.3%
Operating Lease Liabilities Noncurrent	1.8%	0.5%	0.2%	2.5%	0.0%
Other Noncurrent Liabilities	5.0%	4.2%	2.6%	2.2%	2.7%
Total Liabilities	22.9%	22.3%	21.5%	22.4%	26.2%
Equity
Preferred Stock	0.0%	0.0%	0.0%	0.0%	0.0%
Common Stock	0.0%	0.0%	0.0%	0.0%	0.0%
Additional Paid In Capital	34.5%	34.0%	34.3%	34.1%	31.8%
Retained Earnings	88.3%	83.9%	82.4%	79.8%	74.6%
Treasury Stock	45.9%	40.2%	38.0%	35.4%	32.5%
Accumulated Other Comprehensive Income	0.2%	-0.0%	-0.2%	-0.8%	-0.1%
Total Stockholders Equity	77.1%	77.7%	78.5%	77.6%	73.8%
Total Liabilitiesand Equity	100.0%	100.0%	100.0%	100.0%	100.0%

Income Statement

Revenue, expense, and profitability

19 accounts · 5 years

Revenue $14.3B

Operating income $3.6B

Net income $4.5B

Account	2025	2024	2023	2022	2021
IncomeStatement
Revenues Total Revenue	35.4%	37.6%	39.7%	41.7%	63.2%
Expenses Cost of Revenue	26.5%	27.0%	27.4%	25.4%	28.0%
Expenses Research and Development	14.4%	13.6%	13.4%	12.3%	11.2%
Expenses Selling,General and Administrative	6.7%	7.8%	8.0%	7.2%	7.2%
Expenses Depreciation and Amortization	1.3%	1.3%	1.3%	1.2%	1.1%
Expenses Share Based Compensation	2.5%	2.6%	2.7%	2.5%	2.4%
Expenses Operating Expenses	26.5%	27.0%	27.4%	25.4%	28.0%
Other Income Expense Operating Income	8.8%	10.6%	12.2%	16.2%	35.2%
Other Income Expense Interest Income	1.8%	1.9%	1.5%	0.5%	0.2%
Other Income Expense Interest Expense	0.1%	0.1%	0.2%	0.2%	0.2%
Other Income Expense Other Income/expense	4.2%	2.2%	0.7%	0.6%	1.7%
Other Income Expense Income Before Tax	12.9%	12.7%	12.7%	16.6%	36.7%
Income Tax Income Tax Expense	1.8%	1.0%	0.7%	1.8%	4.9%
net Income net Income	11.1%	11.7%	12.0%	14.9%	31.7%
net Income Comprehensive Income	11.3%	11.9%	12.4%	14.1%	31.5%
Earnings Per Share Basic Eps	0.0%	0.0%	0.0%	0.0%	0.0%
Earnings Per Share Diluted Eps	0.0%	0.0%	0.0%	0.0%	0.0%
Earnings Per Share Weighted Average Shares Basic	0.3%	0.3%	0.3%	0.4%	0.4%
Earnings Per Share Weighted Average Shares Diluted	0.3%	0.3%	0.3%	0.4%	0.4%

Cash Flow Statement

Operating, investing, and financing flows

20 accounts · 5 years

Operating cash flow $5.0B

Investing cash flow $-629.1M

Financing cash flow $-3.7B

Account	2025	2024	2023	2022	2021
CashFlow
Operating Activities net Income	11.1%	11.7%	12.0%	14.9%	31.7%
Operating Activities Depreciation and Amortization	1.3%	1.3%	1.3%	1.2%	1.1%
Operating Activities Stock Based Compensation	2.5%	2.6%	2.7%	2.5%	2.4%
Operating Activities Deferred Income Taxes	-1.9%	-2.0%	-2.5%	-2.6%	-0.6%
Operating Activities Changes In Operating Assets and Liabilities	0.2%	4.8%	2.3%	0.6%	10.0%
Operating Activities net Cash From Operating Activities	12.3%	11.7%	13.9%	17.2%	27.8%
Investing Activities Business Acquisitions	0.0%	0.0%	0.2%	0.8%	0.0%
Investing Activities Purchases of Investments	27.0%	44.0%	35.2%	25.6%	27.7%
Investing Activities Proceeds From Sale of Investments	28.5%	39.8%	28.5%	19.0%	8.7%
Investing Activities net Cash From Investing Activities	-1.6%	-6.5%	-9.6%	-13.0%	-21.2%
Financing Activities Repurchase of Common Stock	8.5%	6.9%	6.8%	7.1%	6.5%
Financing Activities Dividends Paid	0.9%	0.0%	0.0%	—	—
Financing Activities Proceeds From Stock Issuance	1.6%	3.9%	3.5%	5.2%	6.6%
Financing Activities Tax Withholding On Stock Based Compensation	1.3%	2.7%	2.1%	1.5%	4.1%
Financing Activities Other Financing Activities	-0.0%	-0.1%	0.0%	0.0%	—
Financing Activities net Cash From Financing Activities	-9.2%	-5.8%	-5.4%	-3.5%	-4.0%
Cash Reconciliation Effect of Exchange Rate On Cash	0.0%	-0.0%	-0.0%	0.0%	0.0%
Cash Reconciliation net Change In Cash	1.6%	-0.7%	-1.2%	0.8%	2.7%
Cash Reconciliation Cash At Beginning of Period	7.7%	6.6%	8.3%	10.7%	11.4%
Cash Reconciliation Cash At End of Period	7.7%	6.6%	8.3%	10.7%	11.4%

Key Ratios

Margins, returns, liquidity, leverage, efficiency

Computed at import · 5 years

Ratio	2025	2024	2023	2022	2021
Profitability
Gross margin	+24.9%	+28.1%	+30.9%	+38.9%	+55.7%
Operating margin	+24.9%	+28.1%	+30.9%	+38.9%	+55.7%
Net margin	+31.4%	+31.1%	+30.1%	+35.6%	+50.2%
FCF margin	—	—	—	—	—
Growth
Revenue CAGR (3y)	+5.6%	-4.0%	+15.6%	+22.9%	+46.2%
Returns
ROE	+14.4%	+15.0%	+15.2%	+19.1%	+43.0%
ROA	+11.1%	+11.7%	+12.0%	+14.9%	+31.7%
ROIC	+9.6%	+11.9%	+14.0%	+18.0%	+39.0%
Liquidity
Current ratio	4.13x	4.73x	5.69x	5.06x	3.56x
Quick ratio	2.03x	2.21x	2.45x	2.69x	2.27x
Leverage
D/E	0.30x	0.29x	0.27x	0.29x	0.36x
Interest coverage	81.69x	72.30x	55.44x	79.78x	156.14x
Efficiency
Asset turnover	0.35x	0.38x	0.40x	0.42x	0.63x
Cash conversion cycle	+223d	+242d	+237d	+249d	+208d

Valuation

Price against fundamentals

FY2025 fundamentals · no price

No price data cached, so there is nothing to multiply. Load prices from the Stock Data tab and this panel reprices itself.

Notes

Your annotations

Not watched

Regeneron Pharmaceuticals

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Recent price history